Investor
Sanofi
CIK 0001121404 · filed 2026-02-11 · SEC filing
13F book
$310.4M
Positions
8
Largest name
31.2%
Meiragtx Hldgs Plc
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Meiragtx Hldgs Plc | — | 12.2M | $97M | 31.2% | — | Held |
| Inhibrx Biosciences, Inc. | INBX | 1.16M | $91.5M | 29.5% | — | Held |
| Novavax Inc | NVAX | 6.88M | $46.2M | 14.9% | — | Held |
| Anaptysbio, Inc | ANAB | 821.9K | $39.8M | 12.8% | — | Held |
| Immuneering Corp | IMRX | 2.71M | $17.8M | 5.7% | — | Held |
| MapLight Therapeutics, Inc. | MPLT | 912K | $16M | 5.2% | — | Held |
| Eledon Pharmaceuticals, Inc. | ELDN | 815K | $1.23M | 0.4% | — | Held |
| Q32 Bio Inc. | QTTB | 244.1K | $810.4K | 0.3% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.